Drug intelligence / Profile preview

anti-CEACAM6 antibody 2A3

Development stage
Preclinical
Lead developer
4Cell Therapies
Modality
Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

anti-CEACAM6 antibody 2A3 is a camelid-derived single-domain antibody (nanobody) that specifically recognizes the carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), with demonstrated cross-reactivity to CEACAM5 due to a conserved epitope within the CEACAM family.[1][3] As a 16 kDa VHH/sdAb and in an engineered heavy-chain antibody format (2A3-mFc), 2A3 has been used as a targeting moiety for molecular imaging and for chimeric antigen receptor (CAR) T-cell constructs, enabling selective recognition and killing of CEACAM6- and CEACAM5-overexpressing tumor cells in preclinical models of pancreatic and breast cancer.[1][3] Radiolabeled and fluorescently labeled 2A3 variants have shown rapid tumor uptake and favorable tumor-to-background ratios in BxPC-3 pancreatic cancer xenografts, supporting its use as a theranostic and targeting tool rather than as a stand-alone therapeutic antibody.[1][3]

Other names
anti-CEACAM6 2A3 single-domain antibodyanti-CEACAM-6 2A3 single-domain antibodyanti-CEACAM 6 2A3 single-domain antibody2A3 single-domain antibody2A3 sdAb2A3 nanobody2A3 heavy chain antibody2A3-mFc
02

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)CEACAM6

Beyond the preview

Go deeper on anti-CEACAM6 antibody 2A3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CEACAM6 antibody 2A3.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call